Form 4: Twist Bioscience CAO Sells Shares for Tax Obligations

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 230 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp (TWST), reported a transaction involving the company's common stock.
• On December 8, 2025, Werner sold 230 shares of common stock at a price of $32.878 per share.
• The sale was a "sell to cover" transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.
• This transaction does not represent a discretionary trade by the reporting person.
• Following the reported transaction, Werner beneficially owns 65,913 shares of Twist Bioscience common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is a neutral event and does not reflect management's sentiment towards the company's prospects.

Positives

• The transaction is a non-discretionary "sell to cover" for tax purposes, which is a routine event and does not signal a lack of confidence from management.

Negatives

• No specific negatives are indicated by this routine, non-discretionary transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This insider transaction is a routine compliance filing and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact, as it's a small, non-discretionary sale for tax purposes, not indicative of a change in management's confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact from this routine insider transaction.

Key Dates

Recommendation

The reported sale by the Chief Accounting Officer is a non-discretionary 'sell to cover' transaction to meet tax obligations associated with RSU vesting. This is a routine event for executives and does not signal any change in the company's fundamentals or management's outlook. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Twist Bioscience, TWST, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Robert F. Werner, Chief Accounting Officer